On 16 January 2014, orphan designation (EU/3/13/1224) was granted by the European Commission to Hope Pharmaceuticals, Ltd., United Kingdom, for sodium nitrite for the treatment of aneurysmal subarachnoid haemorrhage.
The sponsor’s address was updated in March 2019.
|Disease / condition||
Treatment of aneurysmal subarachnoid haemorrhage
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;